We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

77 hedge funds and large institutions have $102M invested in Karyopharm Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

85% more call options, than puts

Call options by funds: $31.3M | Put options by funds: $16.9M

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

47% more capital invested

Capital invested by funds: $69.6M → $102M (+$32.6M)

43.31% more ownership

Funds ownership: 55.52% → 98.83% (+43%)

12% more funds holding

Funds holding: 69 → 77 (+8)

Holders
77
Holders Change
+8
Holders Change %
+11.59%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
32
Reduced
9
Closed
15
Calls
$31.3M
Puts
$16.9M
Net Calls
+$14.4M
Net Calls Change
+$14.3M

Top Buyers

1
CC
Commodore Capital
New York
+$14.9M
2
RCM
RA Capital Management
Massachusetts
+$14.6M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.6M
4
Goldman Sachs
Goldman Sachs
New York
+$7.22M
5
APM
Avidity Partners Management
Texas
+$6.04M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.84M
2
AAA
Affinity Asset Advisors
New York
-$2.97M
3
B
Braidwell
Connecticut
-$2.23M
4
EAM
Exome Asset Management
New York
-$2.18M
5
Ameriprise
Ameriprise
Minnesota
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Commodore Capital
New York
$10.9M +$14.9M +1,950,000 New
RCM
2
RA Capital Management
Massachusetts
$10.7M +$14.6M +1,917,354 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$10.1M +$10.6M +1,385,000 +329%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$8.59M +$386K +50,681 +3%
APM
5
Avidity Partners Management
Texas
$6.44M +$6.04M +792,916 +589%
Goldman Sachs
6
Goldman Sachs
New York
$5.28M +$7.22M +947,579 New
CCM
7
Catalio Capital Management
New York
$5M +$5.75M +754,725 +528%
VCM
8
Vanguard Capital Management
Pennsylvania
$4.12M +$5.64M +739,745 New
IC
9
Ikarian Capital
Texas
$4.09M +$1.44M +188,881 +35%
AAA
10
Affinity Asset Advisors
New York
$2.79M -$2.97M -389,575 -44%
SCM
11
Soleus Capital Management
Connecticut
$2.45M – – –
Millennium Management
12
Millennium Management
New York
$2.34M +$3.21M +420,571 New
BCM
13
Boxer Capital Management
California
$1.69M +$381K +50,000 +20%
DKCM
14
Davidson Kempner Capital Management
New York
$1.67M -$76.4K -10,020 -3%
ACA
15
Acorn Capital Advisors
New York
$1.6M +$2.19M +287,826 New
EP
16
Eversept Partners
New York
$1.54M +$2.11M +276,174 New
JF
17
Jump Financial
Illinois
$1.46M +$1.59M +208,330 +387%
TI
18
Trexquant Investment
Connecticut
$1.44M +$1.65M +216,170 +518%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$1.38M +$1.87M +245,231 +6,582%
BlackRock
20
BlackRock
New York
$1.36M -$20.3K -2,659 -1%
BFM
21
Boothbay Fund Management
New York
$1.19M +$527K +69,182 +48%
BHCM
22
Brevan Howard Capital Management
Jersey
$1.18M +$1.62M +212,367 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$1.15M +$140K +18,399 +10%
UBS Group
24
UBS Group
Switzerland
$1.08M +$805K +105,562 +119%
Group One Trading
25
Group One Trading
Illinois
$1.07M +$679K +89,108 +87%
1
2 3 4

KPTI Hedge Fund Activity: Q1 2026 in Review

77 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2026, worth a combined $102M — up 47% from $69.6M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KPTI positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Commodore Capital, opening a new position worth an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.84M sold.

  • 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2026, up from 69 in Q4 2025.
  • Funds reported $102M of Karyopharm Therapeutics stock for Q1 2026, up 47% quarter-over-quarter.
  • 25 funds opened new Karyopharm Therapeutics positions in Q1 2026 and 15 closed out, a net change of +10 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2026 was Commodore Capital, an estimated $14.9M added.
  • The largest Karyopharm Therapeutics seller in Q1 2026 was Opaleye Management, an estimated $6.84M sold.

Based on aggregated 13F filings for Q1 2026.